Firefly Neuroscience Partners with NeuroSigma to Expand Non-Drug ADHD Care, Stock Soars 42%
AIFF has more than doubled off its 52-week low of $0.618 on elevated volume (54× avg).
Summary
Firefly Neuroscience announced a partnership with NeuroSigma to expand access to the Monarch eTNS System, an FDA-cleared non-drug treatment for pediatric ADHD. Firefly will leverage its AI-powered Evoke platform to introduce the therapy to psychiatry, neurology, and behavioral health practices. The collaboration addresses a large unmet need: nearly one-third of the 6.5 million U.S. children with ADHD receive no treatment, and many families seek alternatives to stimulants. The stock jumped 42% on the news, reflecting investor enthusiasm for a commercial expansion into a sizable market. This follows Firefly's recent biomarker identification for ADHD subtypes and NeuroSigma's July 2026 U.S. launch of its second-generation device with a 1,500-patient waitlist. The partnership could accelerate revenue growth for Firefly, which has faced going concern warnings and dilutive financings. Watch for initial clinician adoption metrics and any revenue contribution in upcoming quarters.
At the time of this announcement, AIFF was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $0.62 to $3.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.